Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | MAX | P61244 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479290 | 0.74 | CYP1A2 (0.38) | GPR3CYP1A2ALDH1A1MAPTRAB9A | |
| SCHEMBL4461176 | 0.74 | GPR3 (0.37) | GPR3ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL411657 | 0.74 | CYP1A2 (0.45) | GPR3CYP1A2ALDH1A1MAPTRAB9A | |
| SCHEMBL1146962 | 0.74 | NCF1 (0.47) | GPR3CYP1A2ALDH1A1MAPTRAB9A | |
| SCHEMBL6179959 | 0.74 | GPR3 (0.37) | GPR3CYP1A2ALDH1A1MAPTRAB9A | |
| SCHEMBL1826639 | 0.74 | MAOA (0.41) | GPR3CYP1A2ALDH1A1MAPTRAB9A | |
| SCHEMBL659910 | 0.72 | ACHE (0.40) | CYP1A2ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL5015215 | 0.72 | ACHE (0.40) | IDO1CYP1A2ALDH1A1MAPTRAB9A | |
| SCHEMBL6448454 | 0.72 | HSD17B10 (0.38) | IDO1CYP1A2ALDH1A1MAPTKMT2A | |
| SCHEMBL16277665 | 0.72 | KDM4E (0.49) | ALDH1A1RAB9AKMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301217-A1 | Selective Glycosidase Inhibitors and Uses Thereof | SIMON FRASER UNIVERSITY (CA) | 2011-12-08 | — | — | US | claimed |
| EP-2344452-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Simon Fraser University (CA) | 2011-07-20 | — | — | EP | claimed |
| WO-2010037207-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2010-04-08 | — | — | WO | claimed |
| US-10808005-B2 | Ligand for orphan nuclear receptor Nur77 and uses thereof | IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED (CN) | 2020-10-20 | — | — | US | disclosed |
| US-20190330261-A1 | LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-3480207-A1 | ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF | Xiamen University (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-9408816-B2 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| EP-2102189-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2099442-B1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS INC (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-0332008-A2 | Peptide-like aminoacid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-09-13 | — | — | EP | disclosed |
| CN-1035286-A | The amino acid derivative of renin-inhibiting | HOECHST AG (DE) | 1989-09-06 | — | — | CN | disclosed |
| EP-0329013-A2 | Renin-inhibiting amino acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
| US-4758584-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0258183-A2 | Process for the preparation of 5-amino-4-hydroxyvaleric-acid derivatives | CIBA-GEIGY AG (CH) | 1988-03-02 | — | — | EP | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0236734-A2 | 5-Amino-4-hydroxyvaleryl derivatives substituted by s-containing groups | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301217-A1 | Selective Glycosidase Inhibitors and Uses Thereof | ENGASE, OGA, GPI | IDO1 711/4885MYC 681/4885MAX 4197/4885 |
| US-10808005-B2 | Ligand for orphan nuclear receptor Nur77 and uses thereof | NR2E3, NR0B1, NR0B2 | IDO1 4818/4885MYC 2469/4885MAX 4815/4885 |
| US-20190330261-A1 | LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF | NR2E3, NR0B1, NR0B2 | IDO1 4818/4885MYC 2469/4885MAX 4815/4885 |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | IDO1 777/4885MYC 4333/4885MAX 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.